Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/oxford-university-press/aminohexane-diphosphonate-in-the-treatment-of-paget-s-disease-of-bone-1ha92Hlwee
References (30)
-
JA Kanis, M Earnshaw, G Heynen, JGG Ledingham, DO Oliver, RGG Russell, CG Woods, P Franchimont, S Gaspar (1977)
Changes in histologic and biochemical indexes of bone turnover after bilateral nephrectomy in patients on hemodialysis., 296
-
A. Paterson, J. Kanis, E. Cameron, D. Douglas, D. Beard, F. Preston, R. Russell (1983)
The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myelomaBritish Journal of Haematology, 54
-
H Shinoda, G Adamek, R Felix, H Fleisch, R Schenk, P Hagan (1983)
Structure‐activity relationships of various bisphosphonates., 35
-
D. P, W., B. Frijlink, Olav, L., M., Bijvoet, J., TE Velde, G., Heynen (1979)
TREATMENT OF PAGET'S DISEASE WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)The Lancet, 313
-
J. Kanis, J. Evanson, R. Russell (1981)
Paget's bloom of bone : Diagnosis and managementMetabolic Bone Disease and Related Research, 3
-
I. Fogelman, L. Smith, R. Mazesss, M. Wilson, J. Bevan (1986)
ABSORPTION OF ORAL DIPHOSPHONATE IN NORMAL SUBJECTSClinical Endocrinology, 24
-
H. Stegemann, K. Stalder (1967)
Determination of hydroxyproline.Clinica chimica acta; international journal of clinical chemistry, 18 2
-
JA Kanis (1984)
Monitoring the treatment of Paget's disease with etidronate., 36
-
C. Preston, A. Yates, M. Beneton, R. Russell, R. Gray, R. Smith, J. Kanis (1986)
Effective short term treatment of Paget's disease with oral etidronate.British Medical Journal (Clinical research ed.), 292
-
J. Kanis, M. Earnshaw, G. Heynen, J. Ledingham, D. Oliver, G. Russell, C. Woods, P. Franchimont, S. Gaspar (1977)
Changes in histologic and biochemical indexes of bone turnover after bilateral nephrectomy in patients on hemodialysis. Evidence for a possible role of endogenous calcitonin.The New England journal of medicine, 296 19
-
B. Boyce, Linda Smith, I. Fogelman, S. Ralston, I. Boyle (1982)
DIPHOSPHONATES AND INHIBITION OF BONE MINERALISATIONThe Lancet, 319
-
A. Yates, T. Jones, K. Mundy, R. Hague, C. Brown, D. Guilland-Cumming, J. Kanis (1984)
Immobilisation hypercalcaemia in adults and treatment with clodronate.British Medical Journal (Clinical research ed.), 289
-
(1980)
Effets compares des traitements a I ’ association calci - tonine - diphosphonate sur les lesions radiologiques de la maladie de Paget -
M. Chapuy, S. Charhon, P. Meunier (1983)
Sustained biochemical effects of short treatment of Paget's disease of bone with dichloromethylene diphosphonate.Metabolic bone disease & related research, 4 6
-
D. Douglas, D. Douglas, C. Preston, C. Preston, M. Prenton, M. Prenton, T. Duckworth, T. Duckworth, J. Kanis, J. Kanis, F. Preston, F. Preston, J. Woodhead, J. Woodhead (1980)
EFFECT OF DICHLOROMETHYLENE DIPHOSPHONATE IN PAGET'S DISEASE OF BONE AND IN HYPERCALCÆMIA DUE TO PRIMARY HYPERPARATHYROIDISM OR MALIGNANT DISEASEThe Lancet, 315
-
A. Yates, R. Gray, G. Urwin, C. Preston, R. Russell, R. Percival, R. Atkins, N. Hamdy, M. Beneton, J. Kanis (1985)
INTRAVENOUS CLODRONATE IN THE TREATMENT AND RETREATMENT OF PAGET'S DISEASE OF BONEThe Lancet, 325
-
G. Yakatan, W. Poynor, R. Talbert, B. Floyd, C. Slough, R. Ampulski, J. Benedict (1982)
Clodronate kinetics and bioavailabilityClinical Pharmacology & Therapeutics, 31
-
R. Altman, C. Johnston, M. Khairi, H. Wellman, A. Serafini, R. Sankey (1973)
Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).The New England journal of medicine, 289 26
-
C. Mautalen, C. Casco, D. González, G. Ghiringhelli, C. Massironi, G. Fromm, L. Plantalech (1984)
Side effects of disodium aminohydroxypropylidenediphosphonate (APD) during treatment of bone diseases.British Medical Journal (Clinical research ed.), 288
-
P. Meunier, C. Alexandre, C. Edouard, L. Mathieu, M. Chapuy, C. Bressot, E. Vignon, U. Trechsel (1979)
EFFECTS OF DISODIUM DICHLOROMETHYLENE DIPHOSPHONATE ON PAGET'S DISEASE OF BONEThe Lancet, 314
-
J. Kanis, J. Evanson, R. Russell (1981)
Paget's disease of bone: diagnosis and management.Metabolic bone disease & related research, 3 4-5
-
André Jung, Alex Chantraine, Alfred Donath, C. Ouwenaller, Dora Turnill, Bernadette Mermillod, Mary Kitler (1983)
Use of dichloromethylene diphosphonate in metastatic bone disease.The New England journal of medicine, 308 25
-
H. Fleisch (1981)
Diphosphonates: history and mechanisms of action.Metabolic bone disease & related research, 3 4-5
-
R. Russell, C. Preston, Roger Smith, R. Walton, C. Woods (1974)
Diphosphonates in Paget's disease.Lancet, 1 7863
-
B. Boyce, I. Fogelman, S. Ralston, Linda Smith, E. Johnston, I. Boyle (1984)
FOCAL OSTEOMALACIA DUE TO LOW-DOSE DIPHOSPHONATE THERAPY IN PAGET'S DISEASEThe Lancet, 323
-
F. Breukelen, O. Bijvoet, A. Oosterom (1979)
INHIBITION OF OSTEOLYTIC BONE LESIONS BY (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)The Lancet, 313
-
R Schenk, P Eggli, H Fleisch, S Rosini (1986)
Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat., 38
-
P. Minaire, E. Bérard, P. Meunier, C. Edouard, G. Goedert, G. Pilonchery (1981)
Effects of disodium dichloromethylene diphosphonate on bone loss in paraplegic patients.The Journal of clinical investigation, 68 4
-
O. Bijvoet, D. Morgan, P. Fourman (1969)
The assessment of phosphate reabsorption.Clinica chimica acta; international journal of clinical chemistry, 26 1
-
C. Johnston, M. Khairi, P. Meunier (1980)
Use of etidronate (EHDP) in Paget's disease of bone.Arthritis and rheumatism, 23 10
- Publisher
- Oxford University Press
- Copyright
- Copyright © 1987 ASBMR
- ISSN
- 0884-0431
- eISSN
- 1523-4681
- DOI
- 10.1002/jbmr.5650020403
- Publisher site
- See Article on Publisher Site
Abstract
We studied the effects of the intravenous or oral administration of aminohexane diphosphonate (AHDP) in 42 patients with active Paget's disease of bone. Treatment of mouth (400 mg daily for 1 month) or intravenously (25 mg or 50 mg daily for 5 days) induced marked suppression of biochemical indices of disease activity. Urinary excretion of hydroxyproline fell to 39 and 42% of pretreatment values (oral and IV treatments respectively), and was followed by a similar decrease in the serum activity of alkaline phosphatase. In both groups of patients, disease activity remained suppressed for the 6 months of followup, and pain improved in 34 out of 37 patients who had bone pain attributed to Paget's disease. Both biopsies indicated that osteoblast and osteoclast numbers decreased with no adverse effects on mineralization. Neither regime was associated with significant side effects. We conclude that short courses of AHDP provide a promising treatment for the long‐term control of Paget's disease.
Journal
Journal of Bone and Mineral Research – Oxford University Press
Published: Aug 1, 1987